RWA Wealth Partners LLC Has $462,000 Position in Zoetis Inc. (NYSE:ZTS)

RWA Wealth Partners LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 25.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,837 shares of the company’s stock after selling 944 shares during the quarter. RWA Wealth Partners LLC’s holdings in Zoetis were worth $462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Norges Bank acquired a new position in Zoetis in the fourth quarter valued at approximately $824,321,000. Raymond James Financial Inc. bought a new stake in shares of Zoetis in the 4th quarter valued at $196,651,000. Polen Capital Management LLC lifted its position in shares of Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. Amundi boosted its stake in Zoetis by 46.2% during the fourth quarter. Amundi now owns 2,748,719 shares of the company’s stock worth $453,355,000 after acquiring an additional 867,993 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in Zoetis by 296.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock worth $144,917,000 after purchasing an additional 665,331 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $161.77 on Wednesday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a fifty day moving average price of $166.26 and a 200-day moving average price of $174.05. The firm has a market cap of $72.44 billion, a price-to-earnings ratio of 29.57, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. UBS Group started coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average target price of $215.90.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last three months. Company insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.